Associated Papers
Small-scale mutations are infrequent as mechanisms of resistance in post-PARP inhibitor tumour samples in high grade serous ovarian cancer.
Burdett NL et al.
Scientific Reports, 2023
38072854 (PubMed )
Supplement: 41598_2023_48153_MOESM1_ESM.xlsx › Supplementary_table_3
p53 Dysregulation in Breast Cancer: Insights on Mutations in the TP53 Network and p53 Isoform Expression.
Steffens Reinhardt L et al.
International Journal of Molecular Sciences, 2023
Uterine Cavity Lavage Mutation Analysis in Lithuanian Ovarian Cancer Patients.
Žilovič D et al.
Cancers, 2023
36765826 (PubMed )
Supplement: cancers-15-00868-s001.zip › cancers-2125909-supplementary.pdf
Germline variation in BRCA1/2 is highly ethnic-specific: Evidence from over 30,000 Chinese hereditary breast and ovarian cancer patients.
Bhaskaran SP et al.
International Journal of Cancer, 2019
30702160 (PubMed )
Supplement: IJC-145-962-s006.xlsx › Total_BRCA1___BRCA2
Functional ex vivo assay to select homologous recombination-deficient breast tumors for PARP inhibitor treatment.
Naipal KA et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2014
Select a paper to view details